Browse the articles below to learn more about our faculty’s latest achievements, awards and honors.
Joshua J. Meeks, MD, PhD, recaps several presentations on bladder cancer from the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.
- 06.25.2022William Catalona, MD, explained the evolution of his views regarding active surveillance in men with low-risk prostate cancer.
Ashley E. Ross, MD, PhD, recaps several presentations on prostate cancer from the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.
Robert E. Brannigan, MD, vice-chair of Clinical Urology, discusses which men with infertility issues should receive genetic testing.
- 06.14.2022A new androgen biosynthesis inhibitor drug improved progression-free survival in prostate cancer but did not improve overall survival compared to current therapies, according to a study co-authored by Maha Hussain, MD.
- 06.01.2022In an interview with Targeted Oncology, William J. Catalona, MD, reviewed the history of active surveillance in the prostate cancer space and how the practice has become more widespread in the United States.
Joshua Halpern, MD, discusses the goals and outcomes of the study, “Elevated follicle stimulating hormone (FSH) predicts decline in semen parameters among men with normal index semen analysis,” which was presented at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.
William Catalona, MD, a panel member at the 2022 annual American Urological Association (AUA) meeting, evaluates data indicating that the number of men with prostate cancer who opted for active surveillance (AS) doubled nationally between 2014 and 2021.
- 05.14.2022Adam B. Murphy, MD, MBA, MSCI, discusses the background and rationale for the study, “Vitamin D has a stronger impact on prostate tumor gene expression in Black men,” which he presented at the 2022 American Urological Association annual meeting in New Orleans.
Investigators at Lurie Cancer Center have identified a gene that drives enzalutamide resistance in advanced prostate cancer, according to research study led by Sarki Abdulkadir, MD.
- 05.10.2022A transcription factor generally associated with androgen receptor activity in prostate cancer has a newly discovered role in controlling lipid biosynthesis, according to a Northwestern Medicine study co-author William Catalona, MD, professor of Urology.
Patients receiving radiotherapy to treat high-risk prostate cancer also benefit from androgen deprivation therapy. The ideal duration of treatment may be roughly two years if receiving external beam radiation and one year if receiving external beam radiation with a brachytherapy boost, according to a study co-authored by Ashley Ross, MD, PhD.
- 05.03.2022This year's grant recipient includes Stephanie J. Kielb, MD, for her work with the International Organization for Women & Development (IOWD).
- 05.01.2022Channa Amarasekera, MD, discusses how the Northwestern Medicine Gay and Bisexual Men's Urology Program is helping heal a community that typically gets overlooked during their urological care.
- 04.22.2022Channa Amarasekera, MD, discusses the impact of the Gay and Bisexual Men’s Urology Program.
- 04.20.2022William J. Catalona, MD, explains why he believes the cancer label is necessary.
Edward M. Schaeffer, MD, PhD and Ashley E. Ross, MD, PhD, discuss the feasibility and outcomes of integrating transperineal prostate biopsy into the outpatient urologic clinic.
- 03.11.2022Dr. Channa Amarasekera talks about the development of the Gay and Bisexual Men’s Urology Program and explains what doctors can do to better support their gay and bisexual prostate cancer patients.
- 03.09.2022Stephanie Kielb, MD, discusses how disability associated with spinal injuries may strongly contribute to lower prostate cancer screening rates.
Ashley E. Ross, MD, PhD, reviews the data and study results from the phase 3 TITAN and phase 3 ARCHES trial in mCSPC.
- 02.23.2022According to a new study co-authored by Maha Hussain, MD, a new drug, administered in combination with standard androgen-deprivation therapy and docetaxel chemotherapy, increased survival in patients with metastatic hormone-sensitive prostate cancer.
- 01.06.2022William J. Catalona, MD, explains how prostate-specific antigen (PSA) testing revolutionized screening and treatment of prostate cancer.
Channa Amarasekera, MD, discusses some of the challenges that sexual minorities face along with ways that clinicians can be more supportive towards this population of patients.
- 12.28.2021Congratulations to Nelson E. Bennett, MD, Robert E. Brannigan, MD, William J. Catalona, MD, Shilajit D. Kundu, MD, Kent T. Perry, MD, Dennis Pessis, MD, and Edward M. Schaeffer, MD.
- 12.07.2021Dr. Channa Amarasekera discusses the new innovative Gay and Bisexual Men’s Urology Program and how it's filling an unmet need, and more.
In an interview with Targeted Oncology, Ashley E. Ross, MD, PhD, discusses new prostate cancer screening and staging options as well as therapies for both earlier and later-stage disease.
Lurie Comprehensive Cancer Center of Northwestern University was awarded a five-year, $9.2 million grant renewal from the National Cancer Institute (NCI) for its continued leadership of a Specialized Programs of Research Excellence (SPORE) in Prostate Cancer.
- Tumor-related risk factors affect conversion of active surveillance to treatment for prostate cancer09.10.2021Study by Dr. William J. Catalona assess the time to conversion from active surveillance to treatment for prostate cancer and provides new data on factors affecting the outcomes of this increasingly used management strategy.
- 09.08.2021From teasing out determinants of health disparities to developing precision medicine treatments, clinicians and scientists from the Lurie Cancer Center are dramatically changing the landscape for all men with prostate cancer.